Glenmark reports Phase IIa data for anti-OX40 mAb in atopic dermatitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a placebo-controlled Phase IIa trial in over 60 patients with moderate to severe atopic dermatitis showing that

Read the full 259 word article

User Sign In